
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its lead drug NUZYRA (omadacycline) for the treatment of pulmonary Nontuberculous Mycobacterial (NTM) disease caused by both Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MAB).
NUZYRA is being investigated in the phase 2b clinical study, currently enrolling subjects for the safety and efficacy in patients with NTM pulmonary disease caused by MAB.